Atossa Genetics (ATOS) Stock Price, News & Analysis

Company Overview

Atossa Genetics, Inc. (NASDAQ: ATOS) is a clinical-stage biotechnology company focused on developing novel therapeutics and diagnostics for breast cancer and other breast-related disorders. The company’s mission centers on improving patient outcomes through targeted therapies and minimally invasive diagnostic tools. Atossa’s research and development efforts are primarily directed toward addressing unmet medical needs in early-stage breast cancer prevention and treatment.

The company’s pipeline includes two lead therapeutic candidates: oral endoxifen, a metabolite of tamoxifen designed for extended-release dosing to reduce systemic side effects, and topical fulvestrant, a formulation intended for localized delivery directly to breast tissue. In addition to its therapeutic programs, Atossa has developed a proprietary microcatheter device for intraductal sampling of nipple aspirate fluid, enabling biomarker analysis and risk assessment without the need for invasive surgical biopsies. This diagnostic platform is being evaluated for its potential to facilitate earlier detection of pre-cancerous changes.

Founded in 2009 and headquartered in Seattle, Washington, Atossa has leveraged strategic collaborations with academic centers and contract research organizations to advance its clinical programs. Under the leadership of President and CEO Steven C. Quay, M.D., Ph.D., the company has completed multiple Phase 1 and Phase 2 trials, generating data that support the safety and feasibility of its drug candidates. Atossa’s management team includes professionals with extensive experience in oncology drug development, regulatory affairs and medical diagnostics.

Atossa Genetics serves patients and healthcare providers in the United States and is pursuing opportunities to expand its global footprint through partnerships and licensing agreements. The company continues to explore additional indications for its platform technologies, including potential applications in other hormone-responsive conditions. By integrating therapeutic and diagnostic innovation, Atossa aims to create a holistic approach to breast health management and offer new solutions for early intervention.

Key Stats

• Today's Range: $0.83 to $0.87
• 50-Day Range: $0.76 to $1.03
• 52-Week Range: $0.55 to $1.66
• Volume: 203,773 shs
• Average Volume: 757,511 shs
• Market Capitalization: $107.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.17
• Consensus Rating: Buy

Atossa Genetics Stock Analysis - MarketRank™

Atossa Genetics scored higher than 32% of companies evaluated by MarketBeat, and ranked 742nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Atossa Genetics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Atossa Genetics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Atossa Genetics are expected to decrease in the coming year, from ($0.22) to ($0.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atossa Genetics is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atossa Genetics is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atossa Genetics has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.22% of the float of Atossa Genetics has been sold short.

Short Interest Ratio / Days to Cover

Atossa Genetics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Atossa Genetics has recently decreased by 2.62%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atossa Genetics does not currently pay a dividend.

Dividend Growth

Atossa Genetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.22% of the float of Atossa Genetics has been sold short.

Short Interest Ratio / Days to Cover

Atossa Genetics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Atossa Genetics has recently decreased by 2.62%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Atossa Genetics this week, compared to 2 articles on an average week.

Search Interest

21 people have searched for ATOS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

5 people have added Atossa Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Atossa Genetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,890.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 8.70% of the stock of Atossa Genetics is held by insiders.

Percentage Held by Institutions

Only 12.74% of the stock of Atossa Genetics is held by institutions.

ATOS Stock Analysis - Frequently Asked Questions

How have ATOS shares performed this year?

Atossa Genetics' stock was trading at $0.9441 on January 1st, 2025. Since then, ATOS stock has decreased by 11.5% and is now trading at $0.8354.

How were Atossa Genetics' earnings last quarter?

Atossa Genetics Inc. (NASDAQ:ATOS) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01.

When did Atossa Genetics' stock split?

Atossa Genetics's stock reverse split on Friday, April 20th 2018.The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Atossa Genetics?

Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Atossa Genetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Atossa Genetics investors own include Zomedica (ZOM), AU Optronics (AUOTY), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), Waste Connections (WCN), American Water Works (AWK) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATOS
• CIK: 1488039
• Web: atossatherapeutics.com
• Phone: (206) 588-0256
• Fax: 206-430-1288
• Employees: 8
• Year Founded: 2009

Price Target and Rating

• Average Stock Price Target: $6.17
• High Stock Price Target: $7.50
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +629.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.50 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -33.90%
• Return on Assets: -31.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.67
• Quick Ratio: 12.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 1.48

Miscellaneous

• Outstanding Shares: 129,170,000
• Free Float: 117,932,000
• Market Cap: $109.25 million
• Optionable: Optionable
• Beta: 0.90